Benoit J Van Den Eynde

List of Publications by Year
in descending order

106 papers	12,066 citations	31976 53 h-index	32842 100 g-index
107 all docs	107 docs citations	107 times ranked	14309 citing authors

#	Article	IF	Citations
1	Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nature Medicine, 2003, 9, 1269-1274.	30.7	2,035
2	Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nature Reviews Cancer, 2014, 14, 135-146.	28.4	925
3	HUMAN T CELL RESPONSES AGAINST MELANOMA. Annual Review of Immunology, 2006, 24, 175-208.	21.8	596
4	Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion. Cancer Research, 2012, 72, 5435-5440.	0.9	591
5	Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2497-2502.	7.1	498
6	Processing of Some Antigens by the Standard Proteasome but Not by the Immunoproteasome Results in Poor Presentation by Dendritic Cells. Immunity, 2000, 12, 107-117.	14.3	374
7	Tumorâ€specific shared antigenic peptides recognized by human T cells. Immunological Reviews, 2002, 188, 51-64.	6.0	356
8	An Antigenic Peptide Produced by Peptide Splicing in the Proteasome. Science, 2004, 304, 587-590.	12.6	297
9	Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues. Cancer Immunology Research, 2015, 3, 161-172.	3.4	292
10	Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape. Trends in Immunology, 2017, 38, 577-593.	6.8	276
11	Tryptophan-Degrading Enzymes in Tumoral Immune Resistance. Frontiers in Immunology, 2015, 6, 34.	4.8	201
12	Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 18599-18604.	7.1	192
13	Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome. Current Opinion in Immunology, 2001, 13, 147-153.	5.5	188
14	An Antigen Produced by Splicing of Noncontiguous Peptides in the Reverse Order. Science, 2006, 313, 1444-1447.	12.6	187
15	Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes. Nature Communications, 2017, 8, 1404.	12.8	177
16	Antigen Spreading Contributes to MAGE Vaccination-Induced Regression of Melanoma Metastases. Cancer Research, 2011, 71, 1253-1262.	0.9	176
17	The Human Vaccines Project: A roadmap for cancer vaccine development. Science Translational Medicine, 2016, 8, 334ps9.	12.4	162
18	A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma. Immunogenetics, 1996, 44, 323-330.	2.4	158

#	Article	IF	Citations
19	Rational Design of 4-Aryl-1,2,3-Triazoles for Indoleamine 2,3-Dioxygenase 1 Inhibition. Journal of Medicinal Chemistry, 2012, 55, 5270-5290.	6.4	153
20	Tryptophan 2,3-Dioxygenase (TDO) Inhibitors. 3-(2-(Pyridyl)ethenyl)indoles as Potential Anticancer Immunomodulators. Journal of Medicinal Chemistry, 2011, 54, 5320-5334.	6.4	151
21	Rational Design of Indoleamine 2,3-Dioxygenase Inhibitors. Journal of Medicinal Chemistry, 2010, 53, 1172-1189.	6.4	146
22	Destructive Cleavage of Antigenic Peptides Either by the Immunoproteasome or by the Standard Proteasome Results in Differential Antigen Presentation. Journal of Immunology, 2006, 176, 1053-1061.	0.8	141
23	Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance. Cancer Immunology Research, 2017, 5, 695-709.	3.4	136
24	Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-Î³. Rheumatology, 2015, 54, 1507-1517.	1.9	125
25	An antigenic peptide produced by reverse splicing and double asparagine deamidation. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E323-31.	7.1	123
26	A New Antigen Recognized by Cytolytic T Lymphocytes on a Human Kidney Tumor Results from Reverse Strand Transcription. Journal of Experimental Medicine, 1999, 190, 1793-1800.	8.5	121
27	Is There a Clinical Future for IDO1 Inhibitors After the Failure of Epacadostat in Melanoma?. Annual Review of Cancer Biology, 2020, 4, 241-256.	4.5	119
28	The Production of a New MAGE-3 Peptide Presented to Cytolytic T Lymphocytes by HLA-B40 Requires the Immunoproteasome. Journal of Experimental Medicine, 2002, 195, 391-399.	8.5	107
29	Database of T cell-defined human tumor antigens: the 2013 update. Cancer Immunity, 2013, 13, 15.	3.2	107
30	An Alternative Open Reading Frame of the Human Macrophage Colony-Stimulating Factor Gene Is Independently Translated and Codes for an Antigenic Peptide of 14 Amino Acids Recognized by Tumor-Infiltrating Cd8 T Lymphocytes. Journal of Experimental Medicine, 2001, 193, 1189-1198.	8.5	98
31	The Cytoplasmic Peptidase DPP9 Is Rate-limiting for Degradation of Proline-containing Peptides. Journal of Biological Chemistry, 2009, 284, 27211-27219.	3.4	95
32	Mouse tumor rejection antigens P815A and P815B : Two epitopes carried by a single peptide. European Journal of Immunology, 1992, 22, 2283-2288.	2.9	94
33	Apoptosis of tumor-infiltrating T lymphocytes: a new immune checkpoint mechanism. Cancer Immunology, Immunotherapy, 2019, 68, 835-847.	4.2	94
34	Tumoral Immune Resistance Mediated by Enzymes That Degrade Tryptophan. Cancer Immunology Research, 2015, 3, 978-985.	3.4	87
35	Splicing of Distant Peptide Fragments Occurs in the Proteasome by Transpeptidation and Produces the Spliced Antigenic Peptide Derived from Fibroblast Growth Factor-5. Journal of Immunology, 2010, 184, 3016-3024.	0.8	84
36	The Final N-Terminal Trimming of a Subaminoterminal Proline-Containing HLA Class I-Restricted Antigenic Peptide in the Cytosol Is Mediated by Two Peptidases. Journal of Immunology, 2002, 169, 4161-4171.	0.8	83

#	Article	IF	Citations
37	Preclinical murine tumor models: A structural and functional perspective. ELife, 2020, 9, .	6.0	81
38	Processing and presentation of tumor antigens and vaccination strategies. Current Opinion in Immunology, 2006, 18, 98-104.	5.5	76
39	Deciphering preferential interactions within supramolecular protein complexes: the proteasome case. Molecular Systems Biology, 2015, 11, 771.	7.2	75
40	Conformational Restraints and Flexibility of 14-Meric Peptides in Complex with HLA-B*3501. Journal of Immunology, 2004, 173, 5610-5616.	0.8	74
41	A Spliced Antigenic Peptide Comprising a Single Spliced Amino Acid Is Produced in the Proteasome by Reverse Splicing of a Longer Peptide Fragment followed by Trimming. Journal of Immunology, 2014, 192, 1962-1971.	0.8	72
42	Differences in the production of spliced antigenic peptides by the standard proteasome and the immunoproteasome. European Journal of Immunology, 2011, 41, 39-46.	2.9	70
43	Proteasome Subtypes and Regulators in the Processing of Antigenic Peptides Presented by Class I Molecules of the Major Histocompatibility Complex. Biomolecules, 2014, 4, 994-1025.	4.0	69
44	Production of an antigenic peptide by insulin-degrading enzyme. Nature Immunology, 2010, 11, 449-454.	14.5	67
45	Analysis of the Processing of Seven Human Tumor Antigens by Intermediate Proteasomes. Journal of Immunology, 2012, 189, 3538-3547.	0.8	67
46	The expression of mouse geneP1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen. , 1997, 70, 349-356.		64
47	Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors. European Journal of Medicinal Chemistry, 2014, 84, 284-301.	5.5	63
48	The shared tumor-specific antigen encoded by mouse geneP1A is a target not only for cytolytic T lymphocytes but also for tumor rejection. European Journal of Immunology, 1998, 28, 4010-4019.	2.9	62
49	Processing of Tumor-Associated Antigen by the Proteasomes of Dendritic Cells Controls In vivo T-Cell Responses. Cancer Research, 2006, 66, 5461-5468.	0.9	60
50	<i>C19orf48</i>Encodes a Minor Histocompatibility Antigen Recognized by CD8+ Cytotoxic T Cells from Renal Cell Carcinoma Patients. Clinical Cancer Research, 2008, 14, 5260-5269.	7.0	59
51	Proteasome subtypes and the processing of tumor antigens: increasing antigenic diversity. Current Opinion in Immunology, 2012, 24, 84-91.	5.5	59
52	Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy. Molecular Cancer Therapeutics, 2018, 17, 2530-2542.	4.1	59
53	Two new tumor-specific antigenic peptides encoded by geneMAGE-C2 and presented to cytolytic T lymphocytes by HLA-A2. International Journal of Cancer, 2004, 109, 698-702.	5.1	57
54	Discovery and preliminary SARs of keto-indoles as novel indoleamine 2,3-dioxygenase (IDO) inhibitors. European Journal of Medicinal Chemistry, 2011, 46, 3058-3065.	5.5	57

#	Article	IF	Citations
55	Comparative Prime-Boost Vaccinations Using Semliki Forest Virus, Adenovirus, and ALVAC Vectors Demonstrate Differences in the Generation of a Protective Central Memory CTL Response against the P815 Tumor. Journal of Immunology, 2007, 178, 6761-6769.	0.8	56
56	Tumor-Initiated Inflammation Overrides Protective Adaptive Immunity in an Induced Melanoma Model in Mice. Cancer Research, 2010, 70, 3515-3525.	0.9	54
57	Deficiency of immunoregulatory indoleamine 2,3-dioxygenase 1in juvenile diabetes. JCI Insight, 2018, 3, .	5.0	51
58	Peptide splicing by the proteasome. Journal of Biological Chemistry, 2017, 292, 21170-21179.	3.4	50
59	A MAGEâ€C2 antigenic peptide processed by the immunoproteasome is recognized by cytolytic T cells isolated from a melanoma patient after successful immunotherapy. International Journal of Cancer, 2011, 129, 2427-2434.	5.1	49
60	Inhibition of Tryptophan-Dioxygenase Activity Increases the Antitumor Efficacy of Immune Checkpoint Inhibitors. Cancer Immunology Research, 2020, 8, 32-45.	3.4	48
61	An Inducible Mouse Model of Melanoma Expressing a Defined Tumor Antigen. Cancer Research, 2006, 66, 3278-3286.	0.9	47
62	Loss of IDO1 Expression From Human Pancreatic Î²-Cells Precedes Their Destruction During the Development of Type 1 Diabetes. Diabetes, 2018, 67, 1858-1866.	0.6	42
63	Tryptophan 2,3-Dioxygenase Expression Identified in Human Hepatocellular Carcinoma Cells and in Intratumoral Pericytes of Most Cancers. Cancer Immunology Research, 2020, 8, 19-31.	3.4	41
64	Long-Peptide Cross-Presentation by Human Dendritic Cells Occurs in Vacuoles by Peptide Exchange on Nascent MHC Class I Molecules. Journal of Immunology, 2016, 196, 1711-1720.	0.8	40
65	Insights into the processing of MHC class I ligands gained from the study of human tumor epitopes. Cellular and Molecular Life Sciences, 2011, 68, 1503-1520.	5.4	37
66	Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development. Leukemia, 2020, 34, 510-521.	7.2	36
67	Epithelial-Mesenchymal-Transition-Like and TGFÎ² Pathways Associated with Autochthonous Inflammatory Melanoma Development in Mice. PLoS ONE, 2012, 7, e49419.	2.5	34
68	Efficiency of the four proteasome subtypes to degrade ubiquitinated or oxidized proteins. Scientific Reports, 2020, 10, 15765.	3.3	29
69	Fully automated radiosynthesis of N1-[18F]fluoroethyl-tryptophan and study of its biological activity as a new potential substrate for indoleamine 2,3-dioxygenase PET imaging. Nuclear Medicine and Biology, 2016, 43, 379-389.	0.6	28
70	Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 159-168.	2.8	27
71	Indoleamine 2,3-dioxygenase inhibitory activity of derivatives of marine alkaloid tsitsikammamine A. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 47-54.	2.2	26
72	Endoplasmic Reticulum Export, Subcellular Distribution, and Fibril Formation by Pmel17 Require an Intact N-terminal Domain Junction. Journal of Biological Chemistry, 2010, 285, 16166-16183.	3.4	25

#	Article	IF	Citations
73	Minimal Tolerance to a Tumor Antigen Encoded by a Cancer-Germline Gene. Journal of Immunology, 2012, 188, 111-121.	0.8	25
74	A tyrosinase peptide presented by HLA-B35 is recognized on a human melanoma by autologous cytotoxic T lymphocytes. , 1999, 83, 755-759.		24
75	Learning from the Proteasome How To Fine-Tune Cancer Immunotherapy. Trends in Cancer, 2017, 3, 726-741.	7.4	23
76	Influenza A Virus Infection Induces Viral and Cellular Defective Ribosomal Products Encoded by Alternative Reading Frames. Journal of Immunology, 2019, 202, 3370-3380.	0.8	23
77	Production of spliced peptides by the proteasome. Molecular Immunology, 2019, 113, 93-102.	2.2	22
78	Functional Differences between Proteasome Subtypes. Cells, 2022, 11, 421.	4.1	22
79	Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance. OncoImmunology, 2015, 4, e1003012.	4.6	21
80	Microenvironment Tumor Metabolic Interactions Highlighted by qMSI: Application to the Tryptophan-Kynurenine Pathway in Immuno-Oncology. SLAS Discovery, 2017, 22, 1182-1192.	2.7	21
81	A peptide derived from melanocytic protein gp100 and presented by HLA-B35 is recognized by autologous cytolytic T lymphocytes on melanoma cells. Tissue Antigens, 2005, 65, 156-162.	1.0	20
82	Cytosolic Processing Governs TAP-Independent Presentation of a Critical Melanoma Antigen. Journal of Immunology, 2018, 201, 1875-1888.	0.8	20
83	Thymocyte-Intrinsic Genetic Factors Influence CD8 T Cell Lineage Commitment and Affect Selection of a Tumor-Reactive TCR. Journal of Immunology, 2004, 172, 5069-5077.	0.8	19
84	The Vacuolar Pathway of Long Peptide Cross-Presentation Can Be TAP Dependent. Journal of Immunology, 2019, 202, 451-459.	0.8	19
85	TNF-Mediated Toxicity After Massive Induction of Specific CD8+ T Cells Following Immunization of Mice with a Tumor-Specific Peptide. Journal of Immunology, 2002, 169, 3053-3060.	0.8	15
86	Navigating Critical Challenges Associated with Immunopeptidomics-Based Detection of Proteasomal Spliced Peptide Candidates. Cancer Immunology Research, 2022, 10, 275-284.	3.4	14
87	Identification of a new peptide recognized by autologous cytolytic T lymphocytes on a human melanoma. Cancer Immunity, 2002, 2, 9.	3.2	14
88	TGFÎ²1 neutralization displays therapeutic efficacy through both an immunomodulatory and a non-immune tumor-intrinsic mechanism. , 2021, 9, e001798.		13
89	Targeting an alternate Wilmsâ€™ tumor antigen 1 peptide bypasses immunoproteasome dependency. Science Translational Medicine, 2022, 14, eabg8070.	12.4	12
90	Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy. , 2021, 9, e003218.		10

#	Article	IF	Citations
91	Rational Design of Original Fused-Cycle Selective Inhibitors of Tryptophan 2,3-Dioxygenase. Journal of Medicinal Chemistry, 2021, 64, 10967-10980.	6.4	9
92	The capture proteasome assay: A method to measure proteasome activity in vitro. Analytical Biochemistry, 2015, 482, 7-15.	2.4	8
93	The capture proteasome assay (CAPA) to evaluate subtype-specific proteasome inhibitors. Data in Brief, 2015, 4, 146-151.	1.0	8
94	Investigation of chalcogen bioisosteric replacement in a series of heterocyclic inhibitors of tryptophan 2,3-dioxygenase. European Journal of Medicinal Chemistry, 2022, 227, 113892.	5.5	8
95	Inefficient exogenous loading of a tapasinâ€dependent peptide onto <scp>HLA</scp>â€<scp>B</scp>*44:02 can be improved by acid treatment or fixation of target cells. European Journal of Immunology, 2012, 42, 1417-1428.	2.9	7
96	Induction of tryptophan 2,3-dioxygenase expression in human monocytic leukemia/lymphoma cell lines THP-1 and U937. International Journal of Tryptophan Research, 2019, 12, 117864691989173.	2.3	7
97	Tryptophanemia is controlled by a tryptophan-sensing mechanism ubiquitinating tryptophan 2,3-dioxygenase. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	5
98	Tryptophan 2,3-Dioxygenase Expression Identified in Murine Decidual Stromal Cells Is Not Essential for Feto-Maternal Tolerance. Frontiers in Immunology, 2020, 11, 601759.	4.8	5
99	Endosomal compartment: Also a dock for MHC class I peptide loading. European Journal of Immunology, 2014, 44, 650-653.	2.9	4
100	T Cellâ€“Mediated Targeted Delivery of Antiâ€“PD-L1 Nanobody Overcomes Poor Antibody Penetration and Improves PD-L1 Blocking at the Tumor Site. Cancer Immunology Research, 2022, 10, 713-727.	3.4	4
101	Tumoral immune resistance based on tryptophan degradation by indoleamine 2,3-dioxygenase. International Congress Series, 2007, 1304, 274-277.	0.2	3
102	Arid5a: A Missing Link between EMT and Tumoral Immune Resistance. Cancer Immunology Research, 2021, 9, 854.	3.4	2
103	Identifying Source Proteins for MHC Class I-Presented Peptides. Methods in Molecular Biology, 2013, 960, 187-207.	0.9	1
104	The shared tumor-specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection. , 1998, 28, 4010.		1
105	New Insights into the Mechanisms of Proteasome-Mediated Peptide Splicing Learned from Comparing Splicing Efficiency by Different Proteasome Subtypes. Journal of Immunology, 2022, 208, 2817-2828.	0.8	1
106	Identifying Antigens Recognized by Cytolytic T Lymphocytes on Tumors. Methods in Molecular Biology, 2019, 1988, 159-186.	0.9	0